News

Lilly Reports Strong Second-Quarter 2010 Results

Nine percent revenue growth driven by higher volume continues strong
trend for the year.
-- 21 percent of Q2 revenue invested in R&D to advance pipeline of nearly
70 potential new medicines in clinical development.
-- Ongoing cost-containment efforts support double-digit growth in
operating income.
-- Q2 earnings per share grow to $1.22 (reported), or $1.24 (non-GAAP).
-- 2010 earnings per share guidance range raised to $4.44 to $4.59
(reported), or $4.50 to $4.65 (non-GAAP), following strong first-half
results.

American Skin Association Receives Major Grant to Create Education Initiative for Teens

American Skin Association has received major funding from Galderma Laboratories to create a ground-breaking new education initiative entitled The Skin You're In. Developed with Scholastic, the global children's publishing, education and media company, the program will provide more than 3 million students (ages 11-15) and 4.5 million parents with the latest information on acne, atopic dermatitis and sun safety.

MELA Sciences Announces FDA Needs More Time to Review MelaFind® PMA Application

MELA Sciences, Inc. announced today that the U.S. Food and Drug
Administration (FDA) has informed the company that it is moving the
General and Plastic Surgery Devices Panel for MelaFind®, which was
originally scheduled for August 26, 2010, to November 2010.

"The FDA informed us today that more time is required to arrange the
meeting," said Joseph V. Gulfo, MD, President & CEO. "We are ready to
go now, and we will maintain our state of preparedness. This is
untimely, however, it is not totally surprising given that the

Johnson & Johnson Reports 2010 Second-Quarter Results

Johnson & Johnson today announced sales of $15.3 billion for the second quarter of 2010, an increase of 0.6% as compared to the second quarter of 2009. Operational results increased 0.1% and the positive impact of currency was 0.5%. Domestic sales declined 2.8%, while international sales increased 4.1%, reflecting operational growth of 3.0% and a positive currency impact of 1.1%.

Laser Treatment Brings Relief to Sufferers of Varicose and Spider Veins

Up until approximately a decade ago, vein stripping was the only means of eradicating unsightly varicose veins. This method involved making an incision in the leg, and using a hooked wire to pull the affected vein out of the body. The invasiveness of vein stripping often resulted in an overnight hospital stay and considerable restriction of physical activity for up to a month. However, since the laser surgery method first became FDA approved ten years ago, it has come a long way in allowing for more convenient, painless and rapid removal of problematic veins.

Signum Biosciences, Inc. Announces Commercial Launch of Arazine™

Signum Biosciences announced that its partner, Rohto Pharmaceutical Co., Ltd., has launched AFC Medirepair® with Signum's compound Arazine™ (n-acetyl-s-farnsylcysteine or AFC) in Japan. Arazine™ is the first compound from Signum's novel anti-inflammatory platform to be commercialized from Signum's pipeline of Signal Transduction Modulators (STMs).

Syneron's eMatrix™ Addresses Global Demand for Treating All Skin Tones

Syneron Medical Ltd., a leading medical aesthetic device innovator,
reports today the growing popularity of eMatrix™ amongst physicians
worldwide in safely and effectively treating all skin tones. Historically,
physicians have struggled to find treatments that could deliver significant
noticeable results for all skin tones while remaining gentle enough
to prevent adverse events. The most common dermatological concerns
for patients with darker skin tones, which include African-American,
Asian, Hispanic, East Indian and other darker skin type patients, are

Insurance Issues Hinder Treatment for 33 Percent of Psoriasis Patients

Results from a new survey reveal that one in three people with psoriasis do not receive proper treatment for their disease due to health insurance issues--and many won't be helped by the new health care reform law.

Approximately 7.5 million Americans have psoriasis, a non-contagious genetic disease that results when faulty signals in the immune system prompt skin cells to regenerate too quickly, causing red, scaly lesions that can crack and bleed. Common treatments for psoriasis include topical and oral medications, UVB light therapy, and injectible biologic drugs.

The Iconic Noxzema® Brand Comes Clean

The iconic Noxzema® brand is back - with new products, updated packaging and the same trusted formulations. The much loved skincare brand, known for its crisp signature scent, has undergone a makeover and is proud to reveal a fresh, new look and products that meet the needs of women today, while still keeping true to its heritage.

Indoor Tanning Association Notes Shortcomings in Release Regarding Melanoma Study

A news release out today from researchers claiming a strong link between indoor tanning and melanoma leaves out critical factors from the study that could lead to very different conclusions, according to the Indoor Tanning Association.